IMMP Stock Risk & Deep Value Analysis
Immutep Ltd
DVR Score
out of 10
What You Need to Know About IMMP Stock
We analyzed Immutep Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IMMP through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
IMMP Risk Analysis & Red Flags
What Could Go Wrong
The company's cash runway is limited to approximately 3-4 quarters. Without significant positive clinical data from TACTI-002 to attract non-dilutive financing or a lucrative partnership, further substantial equity dilution will be necessary to fund operations, severely eroding shareholder value and potentially leading to a reverse stock split or delisting risk.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Continued negative free cash flow with persistent reliance on dilutive equity financing.
- ⚠
History of clinical trial setbacks, notably the AIPAC breast cancer trial miss.
- ⚠
Market capitalization and share price are extremely low for a clinical-stage biotech with advanced assets, reflecting high skepticism.
- ⚠
Intensifying competition in the LAG-3 and broader immuno-oncology space.
Upcoming Risk Events
- 📅
Negative or inconclusive TACTI-002 Phase II/III data readouts
- 📅
Failure to secure sufficient non-dilutive financing, leading to further significant equity dilution
- 📅
Increased competition from other LAG-3 therapies or novel immunotherapies
- 📅
Delays in clinical trial enrollment or regulatory processes
When to Reconsider
- 🚪
Exit if TACTI-002 Phase II data is significantly negative or does not meet clinical relevance thresholds.
- 🚪
Sell if the company announces another highly dilutive capital raise (e.g., >30% dilution) without a clear path to pivotal data or partnership.
- 🚪
Exit if cash runway drops below 2 quarters without an immediate funding solution.
Unlock IMMP Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Immutep represents a high-risk, high-reward investment leveraging its differentiated LAG-3 activator, efti. Despite past clinical setbacks and ongoing financial challenges requiring dilutive funding, the potential for efti as a combination therapy in significant oncology markets like NSCLC and HNSCC, supported by promising TACTI-002 Phase II data, offers substantial upside. Success in pivotal trials and subsequent commercial partnerships could lead to a multi-billion dollar valuation, justifying the current speculative entry.
Is IMMP Stock Undervalued?
Unlock the full AI analysis for IMMP
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IMMP Price Targets & Strategy
12-Month Target
$0.75
Bull Case
$1.50
Bear Case
$0.15
Valuation Basis
Target based on discounted probability-adjusted future milestone payments and an early-stage commercial valuation of efti in NSCLC/HNSCC upon positive Phase II data and clear Phase III pathway.
Entry Strategy
Dollar-cost average between $0.30-$0.40, especially on dips following any market overreaction or near technical support levels. Accumulate ahead of key TACTI-002 data readouts.
Exit Strategy
Take 50% profit at $1.00-$1.20 (post-positive Phase II data); consider full exit if Phase II data is negative or if a highly dilutive capital raise occurs without significant clinical progress. Stop loss at $0.25.
Portfolio Allocation
2% for aggressive risk tolerance only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does IMMP Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
1 Identified
The moat is primarily derived from its patented lead asset, efti, and its unique mechanism. This provides a period of exclusivity if successful. However, the durability is threatened by the extremely high clinical development risk and intense competition from other immuno-oncology approaches.
Moat Erosion Risks
- •Clinical failure of efti in pivotal trials, rendering its IP less valuable.
- •Expiration of key patents or challenges to IP validity.
- •Development of superior or more broadly effective competing therapies (e.g., other LAG-3 inhibitors, novel checkpoints).
IMMP Competitive Moat Analysis
Sign up to see competitive advantages
IMMP Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish to Neutral. Retail sentiment is mixed; some are hopeful for efti's potential, others are highly skeptical due to past setbacks and dilution concerns.
Institutional Sentiment
Neutral. Institutional investors are likely cautious, with some maintaining positions based on long-term potential, but major new institutional buying is probably awaiting de-risking clinical data.
Insider Activity (Form 4)
No significant recent insider activity reported; typical for this stage, watch for any open market buys post-raise as a confidence signal.
Options Flow
Normal options activity; limited volume and open interest typical for a small-cap biotech stock.
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1/CY2026)
Surprise Probability
Low
Historical Earnings Pattern
Stock price reaction is highly volatile and primarily driven by clinical news and financing updates rather than quarterly financial results, which are typically negative for a clinical-stage company.
Key Metrics to Watch
Competitive Position
Top Competitor
Bristol-Myers Squibb (BMY)
Market Share Trend
Not applicable yet (pre-commercial). Currently focused on securing regulatory approval.
Valuation vs Peers
IMMP trades at a significant discount to peers with approved LAG-3 therapies (e.g., Opdualag from BMY) due to its early stage, lack of approved products, and high clinical risk. It is also discounted relative to other clinical-stage biotechs with comparable assets due to its past clinical setbacks and precarious financial position.
Competitive Advantages
- •Unique mechanism of action (MHC Class II agonist) differentiating it from antibody-based LAG-3 blockers.
- •Established safety profile across multiple trials.
- •Strong intellectual property protection for efti.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive IMMP Stock Higher?
Near-Term (0-6 months)
- •Updated TACTI-002 Phase II data for NSCLC (cohort A) and HNSCC (cohort B) – (Estimated Q2 2026)
- •Announcement of Phase III trial design and potential initiation for a key indication (Estimated H2 2026)
- •Potential new preclinical/early-stage clinical data for other efti applications (e.g., subcutaneous formulation)
Medium-Term (6-18 months)
- •Updates on potential strategic partnerships or licensing agreements driven by TACTI-002 data (Estimated 2027)
- •Progress of Phase III trials, including patient enrollment updates (Estimated 2027-2028)
Long-Term (18+ months)
- •Top-line data readout from Phase III pivotal trials (Estimated 2029-2030)
- •Regulatory filings and potential market approval for efti (Estimated 2030+)
- •Establishment of efti as a standard-of-care combination therapy in specific oncology segments
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IMMP?
- ✓
Positive and statistically significant data from upcoming TACTI-002 clinical trial readouts.
- ✓
Announcement of a non-dilutive financing event or a significant upfront payment from a new partnership.
- ✓
Improved cash runway and reduced burn rate without excessive dilution.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Immutep Ltd (IMMP)?
As of March 26, 2026, Immutep Ltd has a DVR Score of 6.6 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the risk level for IMMP stock?
Our analysis rates Immutep Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the IMMP DVR analysis updated?
Our AI-powered analysis of Immutep Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 26, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IMMP (Immutep Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.